Cidara Therapeutics Regains Compliance With Nasdaq's Requirements For Continued Listing
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics has regained compliance with Nasdaq's requirements for continued listing.
May 15, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cidara Therapeutics has regained compliance with Nasdaq's requirements for continued listing, which is positive news for the company's stock.
Regaining compliance with Nasdaq's listing requirements removes the risk of delisting, which is a positive development for the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100